Company news

Harrow, Inc. news in 2025

Harrow, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Harrow to Present at Two Investor Conferences in December

November 23, 2025

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

November 17, 2025

Harrow Announces Third Quarter 2025 Financial Results

November 9, 2025

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

October 26, 2025

ImprimisRx Announces Leadership Changes

October 5, 2025

Harrow to Acquire Melt Pharmaceuticals

September 25, 2025

Harrow Launches Harrow Access for All (HAFA)

September 24, 2025

Harrow Announces Agenda and Speakers for Investor & Analyst Day

September 14, 2025

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

September 7, 2025

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

September 7, 2025

Harrow Announces Second-Quarter 2025 Financial Results

August 10, 2025

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

August 5, 2025

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

July 28, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

July 16, 2025

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

June 17, 2025

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

June 8, 2025

Harrow to Present at Two Investor Conferences in May

May 13, 2025

Harrow Announces First-Quarter 2025 Financial Results

May 7, 2025

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 4, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

April 23, 2025

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

April 9, 2025

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

March 26, 2025

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

March 26, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

March 23, 2025

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

March 16, 2025

Harrow Launches VEVYE® Access for All

March 16, 2025

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

March 10, 2025

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

March 2, 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

January 26, 2025

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

January 6, 2025

Calls in 2025

Decks in 2025